Context Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Context Therapeutics Inc
Access all reports
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for solid tumors. The company's primary focus is on T cell-engaging bispecific antibodies, including its lead candidate, CTIM-76. This investigational therapy targets Claudin 6 (CLDN6), a protein expressed in various solid tumors such as ovarian, endometrial, and testicular cancers, while being minimally present in healthy tissues. Another key candidate in their pipeline is CT-95, a bispecific antibody targeting mesothelin, which is also aimed at treating solid tumors. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
Ticker symbol
CNTX
Country
🇺🇸 United States